Dual Regulator (DIA-39-C20): 30mg

Description

Dia-39-c20 (dual regulator) is a 39-amino acid dual incretin agonist belonging to the peptide receptor modulator research series. it simultaneously targets both the glp-1 receptor (glp-1r) and the gip receptor (gipr), producing synergistic — not merely additive — metabolic effects through co-activation of overlapping downstream signaling pathways. the backbone is engineered from a gip-based scaffold with aib substitutions at positions 2 and 13 for dpp-4 resistance, and carries a c20 fatty diacid (eicosanedioyl) side chain via a γ-glu-2x aeea linker for albumin binding and extended once-weekly half-life. cas: 2023788-19-2. structurally analogous in class to tirzepatide. once-weekly subcutaneous injection. key reference literature: coskun et al. (cell metabolism 2022) — ly3437943 triple receptor agonist, discovery to clinical proof; urva et al. (lancet 2022) — phase 1b multiple-ascending dose trial; jastreboff et al. (nejm 2022) — tirzepatide once weekly for the treatment of obesity (surmount-1).

Specifications

Dose Calculator